Kiadis Pharma announces enrollment of first patients in a multinational registration study for ATIR™
Nov 29th 2009
ATIR™ for reduction of transplant related mortality following an allogeneic stem cell transplantation using a mismatched donor...
read more 
(NL version)
(NL version)
Promising clinical data from Kiadis Pharma’s lead product ATIR™ will be presented at the 51st American Society of Hematology’s (ASH) Annual Meeting
Nov 5th 2009
Biopharmaceutical company Kiadis Pharma announces the presentation of results obtained in two clinical trials with its lead product ATIR™. Dr. Denis...
read more (NL version)
(NL version)
Kiadis Pharma appoints Stefaan Allemeersch as Vice President Business Development
Jun 18th 2009
Amsterdam, 17 June, 2009 – Biopharmaceutical company Kiadis Pharma, focusing on the development of innovative cell based therapeutics in the field of...
read more (NL version)
(NL version)
Kiadis Pharma Press Releases
Kiadis Pharma Press Releases are available via an RSS feed. To add this RSS feed to your reader, right click on the RSS button, click "Copy Shortcut" and add the URL to your feed reader.
Apr 8th 2009
Kiadis Pharma reports ATIR™ clinical data, further supporting its potential in mismatched bone marrow transplantations - ATIR™ data presented at the annual EBMT Presidential Symposium
(NL version)
Feb 6th 2009
Kiadis Pharma’s lead investigator presents results ATIR™ clinical trial at the BMT tandem meeting
(NL version)
Jan 6th 2009
Dec 11th 2008
Dec 8th 2008
Dec 4th 2008
Kiadis Pharma announces positive clinical results for ATIR™ in mismatched bone marrow transplantations - Kiadis Pharma proceeds with pivotal trial ATIR™
(NL version)
Nov 28th 2008
Kiadis Pharma announces continued collaboration with Professor Velardi on its lead product ATIR™
(NL version)
Sep 22nd 2008
May 29th 2008
Kiadis Pharma announces collaboration with the Julius Maximilians University of Würzburg, Germany. Dr. Mielke continues his collaboration with Kiadis Pharma on ATIR™
(NL version)
Apr 15th 2008
Mar 25th 2008
Promising clinical data from Kiadis Pharma’s lead product ATIR™ presented by NIH investigators
(NL version)
Feb 22nd 2008
Kiadis Pharma obtains FDA approval to start a phase III clinical trial for Reviroc™ in the United States. FDA approves IND application for Reviroc™
(NL version)
Jan 31st 2008
Dec 19th 2007
Kiadis Pharma reports successful End of Phase II Meeting with FDA for Reviroc; the FDA offers Special Protocol Assesment for Reviroc
(NL version)
Dec 14th 2007
ATIR classified as “cell based” medicinal product by the EMEA; a classification for innovative new treatments
(NL version)
Nov 28th 2007
Nov 23rd 2007
Nov 19th 2007
Kiadis Pharma continues to provide Rhitol to participating physicians during completion of current clinical study
(NL version)
Nov 7th 2007
Oct 10th 2007
Aug 31st 2007
Aug 17th 2007
Jul 21st 2007
Jul 9th 2007
Jun 26th 2007
